QIAGEN’s CareHPV™ Test Wins WHO Prequalification Status for Cervical Cancer Screening
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
QIAGEN announced the appointment of The Scientific Group, a South Africa-based company and wholly owned subsidiary of Ascendis Medical, as its exclusive commercial partner for Africa, excluding South Africa and the Maghreb. The agreement will raise the profile of QIAGEN’s Sample to Insight solutions in Africa and benefit a region with growing needs for modern molecular testing technologies in healthcare and the life sciences.
“We are very pleased to partner with The Scientific Group, which has decades of experience and vibrant relationships with customers across Africa. QIAGEN and TSG share the vision of making improvements in life possible by bringing the world’s leading Sample to Insight molecular testing solutions to clinical and scientific laboratories, and this agreement is integral to QIAGEN’s growth strategy for the continent,” said Mohammad El-Khoury, QIAGEN’s President and Head of Commercial Operations for the EMEA region.
“We are excited to be able to offer our customers a world-class brand such as QIAGEN, known for its innovative molecular diagnostics and cutting-edge life science solutions. This partnership greatly complements our TSG product portfolio and will form a fundamental part of Ascendis Medical’s ‘Winning Africa’ growth strategy,” added Chris Swanepoel, Managing Director at Ascendis Medical.
QIAGEN will be closely supporting The Scientific Group in developing the market in Africa, including assistance in securing and managing national screening programs using QIAGEN solutions for detection of human papillomavirus (HPV), the primary cause of cervical cancer in women, and latent tuberculosis infection, a key component in strategies to combat the global epidemic of tuberculosis (TB).
QIAGEN currently serves Africa through its office in Fourways, Johannesburg. In addition to its headquarters in Johannesburg, Ascendis Medical has offices in Zambia, Namibia and Botswana, with an established network of distributors and agents in the rest of Africa. The agreement currently excludes the Maghreb countries Morocco, Algeria, Libya, Tunisia, Egypt, Sudan and Eritrea.
“We are very pleased to partner with The Scientific Group, which has decades of experience and vibrant relationships with customers across Africa. QIAGEN and TSG share the vision of making improvements in life possible by bringing the world’s leading Sample to Insight molecular testing solutions to clinical and scientific laboratories, and this agreement is integral to QIAGEN’s growth strategy for the continent,” said Mohammad El-Khoury, QIAGEN’s President and Head of Commercial Operations for the EMEA region.
“We are excited to be able to offer our customers a world-class brand such as QIAGEN, known for its innovative molecular diagnostics and cutting-edge life science solutions. This partnership greatly complements our TSG product portfolio and will form a fundamental part of Ascendis Medical’s ‘Winning Africa’ growth strategy,” added Chris Swanepoel, Managing Director at Ascendis Medical.
QIAGEN will be closely supporting The Scientific Group in developing the market in Africa, including assistance in securing and managing national screening programs using QIAGEN solutions for detection of human papillomavirus (HPV), the primary cause of cervical cancer in women, and latent tuberculosis infection, a key component in strategies to combat the global epidemic of tuberculosis (TB).
QIAGEN currently serves Africa through its office in Fourways, Johannesburg. In addition to its headquarters in Johannesburg, Ascendis Medical has offices in Zambia, Namibia and Botswana, with an established network of distributors and agents in the rest of Africa. The agreement currently excludes the Maghreb countries Morocco, Algeria, Libya, Tunisia, Egypt, Sudan and Eritrea.
